Gene regulation by melatonin linked to epigenetic phenomena

Gene

Volumn 503, Issue 1, 2012, Pages 1-11

  Korkmaz, Ahmet ^a   Rosales Corral, Sergio ^a   Reiter, Russel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cytokines; Epigenetics; Free radicals; Melatonin; Oxidative stress; Transcription

Indexed keywords

CATALASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUTATHIONE PEROXIDASE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; PROTEIN BAX; PROTEIN BCL 2; RETINOID RELATED ORPHAN RECEPTOR ALPHA; SIRTUIN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2;

ACUTE LUNG INJURY; AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE REPRESSION; HEMORRHAGIC CYSTITIS; HISTONE ACETYLATION; HUMAN; LUNG TOXICITY; NEUROPROTECTION; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SPINAL CORD INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CRICETINAE; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION; MELATONIN; MICE; NEOPLASMS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITROGEN OXIDES; OXIDATIVE STRESS; RATS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS;

EID: 84861764997     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.04.040     Document Type: Review

References (176)

1. Adcock I.M., Cosio B., Tsaprouni L., Barnes P.J., Ito K. Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxid. Redox Signal. 2005, 7:144-152.
2. Barlow-Walden L.R., Reiter R.J., Abe M., Pablos M., Menendez-Pelaez A., Chen L.D., Poeggeler B. Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 1995, 26:497-502.
3. Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011, 163:29-43.
4. Baydas G., Reiter R.J., Yasar A., Tuzcu M., Akdemir I., Nedzvetskii V.S. Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. Free Radic. Biol. Med. 2003, 35:797-804.
5. Becker-Andre M., Wiesenberg I., Schaeren-Wiemers N., Andre E., Missbach M., Saurat J.H., Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 1994, 269:28531-28534.
6. Bonnefont-Rousselot D., Collin F., Jore D., Gardes-Albert M. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J. Pineal Res. 2011, 50:328-335.
7. Brzozowska I., Konturek P.C., Brzozowski T., Konturek S.J., Kwiecien S., Pajdo R., Drozdowicz D., Pawlik M., Ptak A., Hahn E.G. Role of prostaglandins, nitric oxide, sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor, l-tryptophan. J. Pineal Res. 2002, 32:149-162.
8. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 2004, 13:853-865.
9. Carrillo-Vico A., Garcia-Maurino S., Calvo J.R., Guerrero J.M. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J. 2003, 17:755-757.
10. Carrillo-Vico A., Garcia-Perganeda A., Naji L., Calvo J.R., Romero M.P., Guerrero J.M. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol. Life Sci. 2003, 60:2272-2278.
11. Carrillo-Vico A., Guerrero J.M., Lardone P.J., Reiter R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27:189-200.
12. Carrillo-Vico A., Lardone P.J., Fernandez-Santos J.M., Martin-Lacave I., Calvo J.R., Karasek M., Guerrero J.M. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J. Clin. Endocrinol. Metab. 2005, 90:992-1000.
13. Casado-Zapico S., Martin V., Garcia-Santos G., Rodriguez-Blanco J., Sanchez-Sanchez A.M., Luno E., Suarez C., Garcia-Pedrero J.M., Menendez S.T., Antolin I., Rodriguez C. Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients. J. Pineal Res. 2011, 50:345-355.
14. Chen L.F., Greene W.C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. 2003, 81:549-557.
15. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 2004, 5:392-401.
16. Chen D., Li Z., Yang Q., Zhang J., Zhai Z., Shu H.B. Identification of a nuclear protein that promotes NF-kappaB activation. Biochem. Biophys. Res. Commun. 2003, 310:720-724.
17. Chetsawang B., Putthaprasart C., Phansuwan-Pujito P., Govitrapong P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J. Pineal Res. 2006, 41:116-123.
18. Choi E.Y., Jin J.Y., Lee J.Y., Choi H.I., Choi I.S., Kim S.J. Melatonin inhibits Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-6 in murine macrophages by suppressing NF-κB and STAT-1 activity. J. Pineal Res. 2011, 50:197-206.
19. Choudhuri S. Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol. Appl. Pharmacol. 2010, 245:378-393.
20. Chuang J.I., Natarajan M., Meltz M.L., Reiter R.J. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol. Int. 1996, 20:687-692.
21. Cini G., Neri B., Pacini A., Cesati V., Sassoli C., Quattrone S., D'Apolito M., Fazio A., Scapagnini G., Provenzani A., Quattrone A. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. J. Pineal Res. 2005, 39:12-20.
22. Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 2007, 275:79-97.
23. Crespo I., Miguel B.S., Laliena A., Alvarez M., Culebras J.M., Gonzalez-Gallego J., Tunon M.J. Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin. J. Pineal Res. 2010, 49:193-200.
24. Crisafulli C., Mazzon E., Muia C., Bella P., Esposito E., Meli R., Cuzzocrea S. Effects of combination of melatonin and dexamethasone on acute lung injury in a mice model of carrageenan-induced pleurisy. J. Pineal Res. 2006, 41:228-237.
25. Cucina A., Proietti S., D'Anselmi F., Coluccia P., Dinicola S., Frati L., Bizzarri M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J. Pineal Res. 2009, 46:172-180.
26. Cuesta S., Kireev R., Forman K., Garcia C., Escames G., Ariznavarreta C., Vara E., Tresguerres J.A. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp. Gerontol. 2010, 45:950-956.
27. Cuzzocrea S., Mazzon E., Serraino I., Lepore V., Terranova M.L., Ciccolo A., Caputi A.P. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J. Pineal Res. 2001, 30:1-12.
28. Dai Y., Rahmani M., Grant S. An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle 2003, 2:467-472.
29. Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108:518-524.
30. Dong W.-G. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 2003, 9:1307-1311.
31. Emanuele S., Lauricella M., Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (review). Int. J. Oncol. 2008, 33:637-646.
32. Espino J., Bejarano I., Paredes S.D., Barriga C., Rodriguez A.B., Pariente J.A. Protective effect of melatonin against human leukocyte apoptosis induced by intracellular calcium overload: relation with its antioxidant actions. J. Pineal Res. 2011, 51:195-206.
33. Esposito E., Genovese T., Caminiti R., Bramonti P., Meli R., Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J. Pineal Res. 2008, 45:166-173.
34. Esposito E., Iacono A., Muia C., Crisafulli C., Mattace Raso G., Bramanti P., Meli R., Cuzzocrea S. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J. Pineal Res. 2008, 44:78-87.
35. Faulk C., Dolinoy D.C. Timing is everything: the when and how of environmentally induced changes in the epigenome of animals. Epigenetics 2011, 6:791-797.
36. Forman K., Vara E., Garcia C., Kireev R., Cuesta S., Acuna-Castroviejo D., Tresguerres J.A. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J. Pineal Res. 2010, 49:312-320.
37. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
38. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physiochemical study. J. Pineal Res. 2011, 51:1-16.
39. Ganguly K., Swarnakar S. Induction of matrix metalloproteinase-9 and -3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J. Pineal Res. 2009, 47:43-55.
40. Ganguly K., Kundu P., Banerjee A., Reiter R.J., Swarnakar S. Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic. Biol. Med. 2006, 41:911-925.
41. Garcia-Macia M., Vega-Naredo I., De Gonzalo-Calvo D., Rodriguez-Gonzalez S.M., Camello P.J., Camello-Almaraz C., Martin-Cano F.E., Rodriguez-Colunga M.J., Pozo M.J., Coto-Montes A.M. Melatonin induces neural SOD2 expression independent of the NF-kappaB pathway and improves the mitochondrial population and function in old mice. J. Pineal Res. 2011, 50:54-63.
42. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Goberna R., Guerrero J.M. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J. Neuroimmunol. 1998, 92:76-84.
43. Genovese T., Mazzon E., Crisafulli C., Esposito E., Di Paola R., Muia C., Di Bella P., Bramanti P., Cuzzocrea S. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J. Pineal Res. 2007, 43:140-153.
44. Gilad E., Cuzzocrea S., Zingarelli B., Salzman A.L., Szabo C. Melatonin is a scavenger of peroxynitrite. Life Sci. 1997, 60:PL169-PL174.
45. Glass C.K., Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 2006, 6:44-55.
46. Gocgeldi E., Uysal B., Korkmaz A., Ogur R., Reiter R.J., Kurt B., Oter S., Topal T., Hasde M. Establishing the use of melatonin as an adjuvant therapeutic against paraquat-induced lung toxicity in rats. Exp. Biol. Med. (Maywood) 2008, 233:1133-1141.
47. Gonca Akbulut, K., Akbulut, H., Akgun, N., Gonul, B., in press. Melatonin decreases apoptosis in gastric mucosa during aging. Aging Clin. Exp. Res.
48. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009, 35:183-192.
49. Hardeland R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integr. Med. 2011, 1:67-81.
50. Hardeland R., Tan D.X., Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47:109-126.
51. Harman D. Free radical theory of aging. Mutat. Res. 1992, 275:257-266.
52. Hasbal C., Aksu B.Y., Himmetoglu S., Dincer Y., Koc E.E., Hatipoglu S., Akcay T. DNA damage and glutathione level in children with asthma bronchiale: effect of antiasthmatic therapy. Pediatr. Allergy Immunol. 2010, 21:e674-e678.
53. Hayes J.D. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 2010, 13:1713-1748.
54. Herceg Z., Vaissieve T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 2011, 6:804-819.
55. Hill S.M., Frasch T., Xiang S., Yuan L., Duplessis T., Mao L. Molecular mechanisms of melatonin anticancer effects. Integr. Cancer Ther. 2009, 8:337-346.
56. Holley A.K., Xu Y., St Clair D.K., St Clair W.H. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann. N. Y. Acad. Sci. 2010, 1201:129-136.
57. Hong Y., Palaksha K.J., Park K., Park S., Kim H.D., Reiter R.J., Chang K.T. Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury. J. Pineal Res. 2010, 49:201-209.
58. Jazirehi A.R. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 2010, 21:805-813.
59. Joo S.S., Yoo Y.M. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J. Pineal Res. 2009, 47:8-14.
60. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., Pestell R.G. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001, 12:73-90.
61. Juknat A.A., Mendez Mdel V., Quaglino A., Fameli C.I., Mena M., Kotler M.L. Melatonin prevents hydrogen peroxide-induced Bax expression in cultured rat astrocytes. J. Pineal Res. 2005, 38:84-92.
62. Jung K.H., Hong S.W., Zheng H.M., Lee D.H., Hong S.S. Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J. Pineal Res. 2009, 47:173-183.
63. Jung K.H., Hong S.W., Zheng H.M., Lee H.S., Lee H., Lee D.H., Lee S.Y., Hong S.S. Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J. Pineal Res. 2010, 48:239-250.
64. Jung-Hynes B., Reiter R.J., Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J. Pineal Res. 2010, 48:9-19.
65. Jung-Hynes B., Schmit T.L., Reagan-Shaw S.R., Siddiqui I.A., Mukhtar H., Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J. Pineal Res. 2011, 50:140-149.
66. Kalaitzidis D., Gilmore T.D. Transcription factor cross-talk: the estrogen receptor and KF-kappaB. Trends Endocrinol. Metab. 2005, 16:46-52.
67. Kang J.W., Koh E.J., Lee S.M. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J. Pineal Res. 2011, 50:403-411.
68. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?. Cell 1998, 93:487-490.
69. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
70. Katoh Y., Itoh K., Yoshida E., Miyagishi M., Fukamizu A., Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 2001, 6:857-868.
71. Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 2011, 286:7629-7640.
72. Kim S.E., Lee M.Y., Lim S.C., Hien T.T., Kim J.W., Ahn S.G., Yoon J.H., Kim S.K., Choi H.S., Kang K.W. Role of Pin1 in neointima formation: down-regulation of Nrf2-dependent heme oxygenase-1 expression by Pin1. Free Radic. Biol. Med. 2010, 48:1644-1653.
73. Kiningham K.K., Xu Y., Daosukho C., Popova B., St Clair D.K. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem. J. 2001, 353:147-156.
74. Konturek P.C., Konturek S.J., Celinski K., Slomka M., Cichoz-Lach H., Bielanski W., Reiter R.J. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J. Pineal Res. 2010, 48:318-323.
75. Korkmaz A. Molecular, genetic and epigenetic pathways of peroxynitrite-induced cellular toxicity. Interdiscip. Toxicol. 2009, 2:219-228.
76. Korkmaz A., Manchester L.C. Reactive nitrogen species; devastating intracellular players and melatonin as a defender. J. Exp. Integr. Med. 2011, 1:63-65.
77. Korkmaz A., Reiter R.J. Epigenetic regulation: a new research area for melatonin?. J. Pineal Res. 2008, 44:41-44.
78. Korkmaz A., Oter S., Deveci S., Ozgurtas T., Topal T., Sadir S., Bilgic H. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J. Urol. 2003, 170:2498-2502.
79. Korkmaz A., Topal T., Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol. Toxicol. 2007, 23:303-312.
80. Korkmaz A., Topal T., Oter S., Tan D.X., Reiter R.J. Hyperglycemia-related pathophysiologic mechanisms and potential beneficial actions of melatonin. Mini Rev. Med. Chem. 2008, 8:1144-1153.
81. Korkmaz A., Reiter R.J., Topal T., Manchester L.C., Oter S., Tan D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med. 2009, 15:43-50.
82. Korkmaz A., Tamura H., Manchester L.C., Ogden G.B., Tan D.X., Reiter R.J. Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line. J. Pineal Res. 2009, 46:115-116.
83. Korkmaz A., Sanchez-Barcelo E.J., Tan D.X., Reiter R.J. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res. Treat. 2009, 115:13-27.
84. Kwak M.-K. Targeting NRF2 signaling for cancer chemoprevention. Toxicol. Appl. Pharmacol. 2010, 244:66-76.
85. Lara E., Mai A., Calvanese V., Altucci L., Lopez-Nieva P., Martinez-Chantar M.L., Varela-Rey M., Rotili D., Nebbioso A., Ropero S., Montoya G., Oyarzabal J., Velasco S., Serrano M., Witt M., Villar-Garea A., Imhof A., Mato J.M., Esteller M., Fraga M.F. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009, 28:781-791.
86. Lardone P.J., Carrillo-Vico A., Molinero P., Rubio A., Guerrero J.M. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production. Cell Mol. Life Sci. 2009, 66:516-525.
87. Lardone P.J., Guerrero J.M., Fernandez-Santos J.M., Rubio A., Martin-Lacave J., Carrillo-Vico A. Melatonin synthesized by T lymphocyrtes as a ligand fothe retinoic acid-related orphan receptor. J. Pineal Res. 2011, 51:454-462.
88. Le Tourneau C., Siu L.L. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Expert Opin. Investig. Drugs 2008, 17:1247-1254.
89. Lee J.M., Li J., Johnson D.A., Stein T.D., Kraft A.D., Calkins M.J., Jakel R.J., Johnson J.A. Nrf2, a multi-organ protector?. FASEB J. 2005, 19:1061-1066.
90. Leja-Szpak A., Jaworek J., Pierzchalski P., Reiter R.J. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J. Pineal Res. 2010, 49:248-255.
91. Li W., Kong A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 2009, 48:91-104.
92. Li J.H., Yu J.P., Yu H.G., Xu X.M., Yu L.L., Liu J., Luo H.S. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005, 2005:185-193.
93. Li W., Khor T.O., Xu C., Shen G., Jeong W.S., Yu S., Kong A.N. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 2008, 76:1485-1489.
94. Li W., Thakor N., Xu E.Y., Huang Y., Chen C., Yu R., Holcik M., Kong A.N. An internal ribosomal entry site mediates redox-sensitive translation of Nrf2. Nucleic Acids Res. 2010, 38:778-788.
95. Ling X., Zhang L.M., Lu S.D., Li X.J., Sun F.Y. Protective effect of melatonin on injuried cerebral neurons is associated with bcl-2 protein over-expression. Zhongguo Yao Li Xue Bao 1999, 20:409-414.
96. Lu S.C. Regulation of glutathione synthesis. Mol. Aspects Med. 2009, 30:42-59.
97. Maity P., Bindu S., Dey S., Goyal M., Alam A., Pal C., Reiter R., Bandyopadhyay U. Melatonin reduces indomethacin-induced gastric mucosal cell apoptosis by preventing mitochondrial oxidative stress and the activation of mitochondrial pathway of apoptosis. J. Pineal Res. 2009, 46:314-323.
98. Malins D.C., Polissar N.L., Gunselman S.J. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2557-2563.
99. Marchion D., Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert. Rev. Anticancer. Ther. 2007, 7:583-598.
100. Masri S., Sassone-Corsi P. Plasticity and specificity of the circadian epigenome. Nat. Neurosci. 2010, 13:1324-1329.
101. Mathers J.C. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 2010, 71:3-39.
102. Mathes A.M. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J. Gastroenterol. 2010, 16:6087-6097.
103. Mattson M.P., Culmsee C., Yu Z., Camandola S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J. Neurochem. 2000, 74:443-456.
104. Mayo J.C., Sainz R.M., Tan D.X., Hardeland R., Leon J., Rodriguez C., Reiter R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol. 2005, 165:139-149.
105. Mediavilla M.D., Sanchez-Barcelo E.J., Tan D.X., Manchester L., Reiter R.J. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 2010, 17:4462-4481.
106. Melchiorii D., Reiter R.J., Sewerynek E., Hara M., Chen L.D., Nistico G. Paraquat toxicity and oxidative damage: reduction by melatonin. Biochem. Pharmacol. 1996, 51:1095-1099.
107. Mercado N., Thimmulappa R., Thomas C.M., Fenwick P.S., Chana K.K., Donnelly L.E., Biswal S., Ito K., Barnes P.J. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 2011, 406:292-298.
108. Mollace V., Muscoli C., Masini E., Cuzzocrea S., Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev. 2005, 57:217-252.
109. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011, 21:103-115.
110. Natarajan M., Sadeghi K., Reiter R.J., Meltz M.L. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem. Mol. Biol. Int. 1995, 37:1063-1070.
111. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J. Pineal Res. 2011, 50:124-131.
112. Oter S., Korkmaz A., Oztas E., Yildirim I., Topal T., Bilgic H. Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol. Res. 2004, 32:185-189.
113. Ozbek E., Ilbey Y.O., Ozbek M., Simsek A., Cekmen M., Somay A. Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression. J. Endourol. 2009, 23:1165-1173.
114. Ozcan A., Korkmaz A., Oter S., Coskun O. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. Arch. Toxicol. 2005, 79:461-465.
115. Pablos M.I., Agapito M.T., Gutierrez R., Recio J.M., Reiter R.J., Barlow-Walden L., Acuna-Castroviejo D., Menendez-Pelaez A. Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J. Pineal Res. 1995, 19:111-115.
116. Pablos M.I., Reiter R.J., Ortiz G.G., Guerrero J.C., Agapito M.T., Chuang J.I. Rhythms of glutathione peroxidase and glutathione reductase in the brain of chick and their inhibition by light. Neurochem. Int. 1998, 32:69-75.
117. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 2006, 17:321-327.
118. Peck B., Chen C.Y., Ho K.K., Di Fruscia P., Myatt S.S., Coombes R.C., Fuchter M.J., Hsiao C.D., Lam E.W. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 2010, 9:844-855.
119. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
120. Perkins N.D., Gilmore T.D. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13:759-772.
121. Perkins N.D., Felzien L.K., Betts J.C., Leung K., Beach D.H., Nabel G.J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997, 275:523-527.
122. Peyrot F., Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J. Pineal Res. 2008, 45:235-246.
123. Radogna F., Cristofanon S., Paternoster L., D'Alessio M., De Nicola M., Cerella C., Dicato M., Diederich M., Ghibelli L. Melatonin antagonizes the intrinsic pathway of apoptosis via mitochondrial targeting of Bcl-2. J. Pineal Res. 2008, 44:316-325.
124. Rahman I., Antonicelli F., MacNee W. Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells. J. Biol. Chem. 1999, 274:5088-5096.
125. Rahman I., Gilmour P.S., Jimenez L.A., MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem. 2002, 234-235:239-248.
126. Ram P.T., Dai J., Yuan L., Dong C., Kiefer T.L., Lai L., Hill S.M. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002, 179:141-150.
127. Reiter R.J. Circannual reproductive rhythms in mammals related to photoperiod and pineal function: a review. Chronobiologia 1974, 1:365-395.
128. Reiter R.J., Richardson B.A., Johnson L.Y., Ferguson B.N., Dinh D.T. Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science 1980, 210:1372-1373.
129. Reiter R.J., Craft C.M., Johnson J.E., King T.S., Richardson B.A., Vaughan G.M., Vaughan M.K. Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 1981, 109:1295-1297.
130. Reiter R.J., Tan D.X., Manchester L.C., Lopez-Burillo S., Sainz R.M., Mayo J.C. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv. Exp. Med. Biol. 2003, 527:539-548.
131. Reiter R.J., Tan D.X., Manchester L.C., Pilar Terron M., Flores L.J., Koppisetti S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007, 52:11-28.
132. Reiter R.J., Paredes S.D., Manchester L.C., Tan D.X. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 2009, 44:175-200.
133. Reiter R.J., Tan D.X., Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J. Hypertens. 2009, (Suppl. 27):S17-S20.
134. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog. Brain Res. 2010, 181:127-151.
135. Reiter R.J., Tan D.X., Sanchez-Barcelo E., Mediavilla M.D., Gitto E., Korkmaz A. Circadian mechanisms in the regulation of melatonin synthesis: disruption with light at night and the pathophysiological consequences. J. Exp. Integr. Med. 2011, 1:13-22.
136. Reiter, R. J., Tan, D. X., Korkmaz, A., Ma, S., in press. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann. Med.
137. Ressmeyer A.R., Mayo J.C., Zelosko V., Sainz R.M., Tan D.X., Poeggeler B., Antolin I., Zsiznik B.K., Reiter R.J., Hardeland R. Antioxidant properties of the melatonin metabolite, N1-acetyl-5-methoxykynuramine: scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003, 8:203-213.
138. Rizzo G., Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr. Opin. Pharmacol. 2006, 6:421-427.
139. Rodriguez C., Mayo J.C., Sainz R.M., Antolin I., Herrera F., Martin V., Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 2004, 36:1-9.
140. Rosales-Corral S., Reiter R.J., Tan D.X., Ortiz G.G., Lopez-Armas G. Functional aspects of redox control during neuroinflammation. Antioxid. Redox Signal. 2010, 13:193-247.
141. Sadir S., Deveci S., Korkmaz A., Oter S. Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats. Cell Biochem. Funct. 2007, 25:521-526.
142. Sainz R.M., Mayo J.C., Rodriguez C., Tan D.X., Lopez-Burillo S., Reiter R.J. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol. Life Sci. 2003, 60:1407-1426.
143. Sasaki M., Jordan P., Joh T., Itoh M., Jenkins M., Pavlick K., Minagar A., Alexander S.J. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol. 2002, 2:9.
144. Sharma R., Ottenhof T., Rzeczkowska P.A., Niles L.P. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J. Pineal Res. 2008, 45:277-284.
145. Siu S.W., Lau K.W., Tam P.C., Shiu S.Y. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002, 52:106-122.
146. Smirnov A.N. Nuclear melatonin receptors. Biochemistry (Mosc) 2001, 66:19-26.
147. Song Y.S., Lee Y.S., Chan P.H. Oxidative stress transiently decreases the IKK complex (IKKalpha, beta, and gamma), an upstream component of NF-kappaB signaling, after transient focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 2005, 25:1301-1311.
148. Song Y.S., Lee Y.S., Narasimhan P., Chan P.H. Reduced oxidative stress promotes NF-kappaB-mediated neuroprotective gene expression after transient focal cerebral ischemia: lymphocytotrophic cytokines and antiapoptotic factors. J. Cereb. Blood Flow Metab. 2007, 27:764-775.
149. Steinhilber D., Brungs M., Werz O., Wiesenberg I., Danielsson C., Kahlen J.P., Nayeri S., Schrader M., Carlberg C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J. Biol. Chem. 1995, 270:7037-7040.
150. Sudnikovich E.J., Maksimchik Y.Z., Zabrodskaya S.V., Kubyshin V.L., Lapshina E.A., Bryszewska M., Reiter R.J., Zavodnik I.B. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur. J. Pharmacol. 2007, 569:180-187.
151. Sun Y., Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 1996, 21:335-348.
152. Sun Z., Chin Y.E., Zhang D.D. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol. Cell. Biol. 2009, 29:2658-2672.
153. Swarnakar S., Mishra A., Ganguly K., Sharma A.V. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J. Pineal Res. 2007, 43:56-64.
154. Swarnakar S., Paul S., Jingh L.P., Reiter R.J. Matrix metalloproteinases in health and disease: regulation by melatonin. J. Pineal Res. 2011, 50:8-20.
155. Tamura E.K., Cecon E., Monteiro A.W., Silva C.L., Markus R.P. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J. Pineal Res. 2009, 46:268-274.
156. Tan D.X., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin; a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1993, 57-60.
157. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
158. Tan D.X., Manchester L.C., Fuentes-Broto I., Paredes S.D., Reiter R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes. Rev. 2011, 12:167-188.
159. Tocharus J., Khonthun C., Chongthammakun S., Govitrapong P. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J. Pineal Res. 2010, 48:347-352.
160. Tomas-Zapico C., Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res. 2005, 39:99-104.
161. Tomas-Zapico C., Boga J.A., Caballero B., Vega-Naredo I., Sierra V., Alvarez-Garcia O., Tolivia D., Rodriguez-Colunga J.M., Coto-Montes A. Coexpression of MT1 and RORalpha1 melatonin receptors in the Syrian hamster Harderian gland. J. Pineal Res. 2005, 39:21-26.
162. Topal T., Oztas Y., Korkmaz A., Sadir S., Oter S., Coskun O., Bilgic H. Melatonin ameliorates bladder damage induced by cyclophosphamide in rats. J. Pineal Res. 2005, 38:272-277.
163. Tripathi D.N., Jena G.B. Effect of melatonin on the expression of Nrf2 and NF-kappaB during cyclophosphamide-induced urinary bladder injury in rat. J. Pineal Res. 2010, 48:324-331.
164. Ucar M., Korkmaz A., Reiter R.J., Yaren H., Oter S., Kurt B., Topal T. Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol. Lett. 2007, 173:124-131.
165. Urata Y., Honma S., Goto S., Todoroki S., Iida T., Cho S., Honma K., Kondo T. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med. 1999, 27:838-847.
166. Verdin E., Hirschey M.D., Finley L.W., Haigis M.C. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci. 2010, 35:669-675.
167. Vijayalaxmi, Thomas C.R., Reiter R.J., Herman T.S. Melatonin: from basic research to cancer treatment clinics. J. Clin. Oncol. 2002, 20:2575-2601.
168. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009, 15:345-357.
169. Wang T., Zhang X., Li J.J. The role of NF-kappaB in the regulation of cell stress responses. Int. Immunopharmacol. 2002, 2:1509-1520.
170. Wiesenberg I., Missbach M., Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor. Neurol. Neurosci. 1998, 12:143-150.
171. Winiarska K., Fraczyk T., Malinska D., Drozak J., Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J. Pineal Res. 2006, 40:168-176.
172. Witzel I.I., Koh L.F., Perkins N.D. Regulation of cyclin D1 gene expression. Biochem. Soc. Trans. 2010, 38:217-222.
173. Xiao C., Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv. Exp. Med. Biol. 2005, 560:41-45.
174. Xu Y., Kiningham K.K., Devalaraja M.N., Yeh C.C., Majima H., Kasarskis E.J., St Clair D.K. An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol. 1999, 18:709-722.
175. Yildirim I., Korkmaz A., Oter S., Ozcan A., Oztas E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother. Pharmacol. 2004, 54:469-473.
176. Zhu M., Fahl W.E. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem. Biophys. Res. Commun. 2001, 289:212-219.